Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Biohaven Ltd (BHVN)

Biohaven Ltd (BHVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Canada Jobs in Focus Next Week Baystreet - Fri May 3, 4:47PM CDT

Monday U.S. Featured Earnings Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (Q1) EPS of $3.66, ...

VRTX : 422.78 (+0.90%)
MCHP : 91.50 (+0.02%)
PLTR : 20.60 (-2.55%)
DIS : 105.79 (-0.01%)
ANET : 314.03 (+6.07%)
TM : 218.78 (-3.72%)
UBER : 66.99 (-1.38%)
ABNB : 146.32 (-0.50%)
HMC : 33.78 (-0.47%)
CEG : 214.93 (-0.45%)
RBLX : 31.45 (+3.39%)
BHVN : 35.69 (-13.71%)
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® PR Newswire - Mon Oct 16, 2023

- Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscular disorders and metabolic diseases including...

BHVN : 35.69 (-13.71%)
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire - Thu Oct 5, 2023

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 35.69 (-13.71%)
Wall Street - NYSE Full View
Markets Today: Stocks Decline as Bond Yields Soar Barchart - Tue Oct 3, 2023

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.61%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.76%. Stock index futures this morning are moderately lower, weighed...

ESM24 : 5,246.25s (+0.14%)
NQM24 : 18,255.00s (+0.22%)
MCK : 559.91 (+0.86%)
BHVN : 35.69 (-13.71%)
ABNB : 146.32 (-0.50%)
KLG : 21.77 (-1.94%)
HPQ : 29.72 (+0.24%)
DOW : 59.41 (-0.07%)
LYB : 101.37 (-0.26%)
FVRR : 23.52 (+4.95%)
DY : 150.57 (-0.31%)
PNT : 12.50 (+0.16%)
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares PR Newswire - Mon Oct 2, 2023

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 35.69 (-13.71%)
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES PR Newswire - Mon Oct 2, 2023

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 35.69 (-13.71%)
Why Biohaven Stock Is Skyrocketing Today Motley Fool - Wed Sep 27, 2023

Promising clinical trial data led investors to bid the stock up, adding to its solid year-to-date gain.

BHVN : 35.69 (-13.71%)
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy PR Newswire - Thu Sep 14, 2023

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and...

BHVN : 35.69 (-13.71%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN PR Newswire - Fri Aug 18, 2023

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are...

BHVN : 35.69 (-13.71%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN PR Newswire - Thu Aug 10, 2023

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are...

BHVN : 35.69 (-13.71%)

Barchart Exclusives

3 Stocks Under $10 to Keep an Eye On Barchart - Sat May 11, 7:30AM CDT
These under-$10 stocks have solid fundamentals and promising growth prospects, making them worthy of investors’ attention for long-term investments. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot